Maintenance Defactinib Versus Placebo After First-Line Chemotherapy in Patients With Merlin-Stratified Pleural Mesothelioma: COMMAND-A Double-Blind, Randomized, Phase II Study.

A Fennell, Dean; Baas, Paul; Taylor, Paul; K Nowak, Anna; Gilligan, David; Nakano, Takashi; A Pachter, Jonathan; T Weaver, David; Scherpereel, Arnaud; Pavlakis, Nick; P van Meerbeeck, Jan; Cedrés, Susana; Nolan, Luke; Kindler, Hedy; G J V Aerts, Joachim

doi:10.1200/JCO.2018.79.0543

Public

Maintenance Defactinib Versus Placebo After First-Line Chemotherapy in Patients With Merlin-Stratified Pleural Mesothelioma: COMMAND-A Double-Blind, Randomized, Phase II Study.

Shared by NobleBlocks on Apr 1, 2019 • 12:00 AM UTC

Authors:

Dean A Fennell

Paul Baas

Paul Taylor

Abstract

PURPOSE: Inhibition of focal adhesion kinase has been shown to selectively kill mesothelioma cells that express low levels of moesin-ezrin-radixin-like protein (merlin). On this basis, we designed a randomized, phase II trial to investigate whether defactinib as maintenance therapy after standard fi...

Discussions